Hip pain, ADL function, sport function and quality of life outcomes meta-analysis and sensitivity analysis
| Domain | Follow-up time | Score | MIC | All studies | Sensitivity analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Studies included | WMD (95% CI) | τ2 | I2 | Studies included | WMD (95% CI) | τ2 | I2 | ||||
| Pain | <3 mos | VAS | 30 | 26 50 | 31 (22 to 40) | 43* | 67 | 50 | 19 (7 to 31) | − | |
| 3 to <6 mos | VAS | 30 | 26 29 50 | 37 (24 to 50) | 167* | 92 | 29 50 | 26 (19 to 32) | 1 | 4 | |
| HAGOS, HOOS | 9 | 36 49 | 18 (16 to 21) | 0 | 0 | 36 | 17 (9 to 25) | − | |||
| 6 mos to <1 year | VAS | 30 | 26 29 48 | 45 (37 to 53) | 51* | 78 | 28 48 | 39 (30 to 47) | 14 | 38 | |
| 1 to <2 years | VAS | 30 | 26 29 48 | 40 (27 to 54) | 171* | 92 | 29 48 | 28 (22 to 35) | 0 | 0 | |
| 2 to <3 years | VAS | 30 | 25 26 28 35 45 | 42 (37 to 46) | 26* | 72 | 25 | 40 (34 to 46) | − | ||
| 3 to <4 years | VAS, NRS | 30 | 26 39 | 37 (13 to 50) | 431* | 97 | − | − | − | ||
| 4 to <5 years | VAS | 30 | 26 40 | 44 (39 to 50) | 12 | 56 | − | − | − | ||
| ADL function | 3 to <6 mos | HAGOS, HOOS | 9 | 36 49 | 18 (15 to 21) | 0 | 0 | 36 | 18 (9 to 27) | − | |
| 6 mos to <1 year | HOS | 9 | 31 ∼ | 22 (17 to 27) | 0 | 0 | 31 ∼ | 22 (17 to 27) | 0 | 0 | |
| 1 to <2 years | HOS | 9 | 30 31 39 | 18 (13 to 24) | 19* | 64 | 30 31 | 21 (16 to 26) | 5 | 26 | |
| 2 to <3 years | HOS | 9 | 28 31 34 38 42 | 24 (20 to 28) | 19* | 65 | 31 34 42 | 23 (19 to 27) | 6 | 30 | |
| 3 to <4 years | HOS | 9 | 39 44 | 17 (8 to 25) | 32* | 85 | − | − | − | ||
| ≥5 years | HOS | 9 | 27 | 10 (7 to 13) | − | − | − | − | |||
| Sport function | 3 to <6 mos | HAGOS, HOOS | 10 | 36 49 | 19 (16 to 22) | 0 | 0 | 36 | 17 (6 to 28) | − | |
| 6 mos to <1 year | HOS | 6 | 31 ∼ | 33 (19 to 47) | 64 | 61 | 31 ∼ | 33 (19 to 47) | 64 | 61 | |
| 1 to <2 years | HOS | 6 | 30 31 | 38 (30 to 45) | 9 | 23 | 30 31 | 38 (30 to 45) | 9 | 23 | |
| 2 to <3 years | HOS | 6 | 28 31 34 38 42 | 41 (29 to 53) | 261* | 93 | 31 34 42 | 39 (29 to 49) | 100* | 80 | |
| 3 to <4 years | HOS | 6 | 44 | 30 (24 to 36) | − | − | − | − | |||
| ≥5 years | HOS | 6 | 27 | 31 (27 to 34) | − | − | − | − | |||
| Quality of life | 3 to <6 mos | HAGOS, HOOS | 11 | 36 49 | 19 (16 to 22) | 0 | 0 | 36 | 17 (8 to 26) | − | |
HAGOS, Copenhagen Hip and Groin Outcome Score; HOOS, Hip dysfunction and Osteoarthritis Outcome Score; HOS, Hip Outcome Score; I2, degree of heterogeneity; MIC, minimal important change; NRS, numeric rating scale; τ2, between-study variance; VAS, visual analogue scale; WMD, weighted mean difference.
∼ Only one study but with two groups; therefore, analysis of τ2 and I2 was possible.
*Between-study variance significant at p<0.05.